Europe has moved significantly closer to authorizing a cannabidiol product as a conventional food supplement after the European Food Safety Authority issued a positive safety opinion for a highly purified form of synthetic CBD. The decision represents one of the most important regulatory developments for Europe’s CBD industry since cannabidiol products were brought under the European Union’s novel food system. EFSA’s Panel on Nutrition, Novel Foods and Food Allergens concluded that the synthetic cannabidiol under review can be considered safe at an intake of up to 2 milligrams per day under narrowly defined conditions of use.
The opinion does not itself constitute legal authorization to sell the product throughout the European Union. That authority rests with the European Commission, which must now consider EFSA’s scientific assessment, prepare an implementing measure and obtain the necessary support from EU member states before adding the product to the Union list of authorized novel foods. Still, a favorable EFSA opinion removes one of the largest scientific barriers that has prevented CBD supplements from completing the EU approval process. If the Commission ultimately grants authorization, the product could become one of the first major CBD novel foods formally cleared through Europe’s modern food-safety system.
EFSA Finds Synthetic CBD Safe at a Strict 2-Milligram Daily Level
The scientific opinion concerns synthetic cannabidiol submitted by Chanelle McCoy CBD Ltd., which first applied to the European Commission for novel food authorization in March 2020. The ingredient consists of at least 98 percent pure CBD produced through chemical synthesis rather than extraction from Cannabis sativa. The applicant intends for the cannabidiol to be dissolved in medium-chain triglyceride, or MCT, oil and marketed as a food supplement. EFSA ultimately evaluated a proposed maximum intake of 2 milligrams of CBD per day for adults aged 25 and older, excluding pregnant and breastfeeding women.
EFSA concluded that the ingredient was safe at that level under the proposed conditions of use, with one major exception: the agency said safety could not be established for people taking medications. That restriction reflects continuing concerns about CBD’s ability to interact with enzymes involved in drug metabolism. The assessment also does not extend the same safety conclusion to people under 25, pregnant or breastfeeding consumers, or formulations that fall outside the specifications evaluated by EFSA. Rather than serving as a blanket endorsement of CBD supplements, the opinion establishes a relatively narrow safety pathway for a highly purified, carefully characterized product consumed at a low daily dose.
The Applicant Originally Sought a Much Higher CBD Dose
One of the most revealing details in the EFSA assessment is how substantially the proposed dose changed during the regulatory process. Chanelle McCoy CBD initially sought permission for its synthetic cannabidiol to be consumed at up to 25 milligrams per day. That level would have been much closer to the serving sizes commonly associated with commercial CBD oils and supplements. Following EFSA’s broader reassessment of cannabidiol safety, however, the applicant revised its proposed conditions of use and reduced the maximum daily amount to just 2 milligrams.
The revision reflects EFSA’s updated provisional safe intake level for highly purified CBD. In early 2026, the agency established a provisional intake of approximately 0.0275 milligrams per kilogram of body weight per day, equivalent to roughly 2 milligrams for a 70-kilogram adult. EFSA applied a large uncertainty factor because significant gaps remain in the scientific evidence concerning long-term CBD consumption. That conservative approach allowed regulators to identify a level they considered sufficiently protective even though major questions about prolonged exposure, reproduction, neurological effects and other health outcomes have not yet been completely resolved.
Europe’s CBD Safety Review Has Been Years in the Making
The new opinion marks a substantial change from EFSA’s position only a few years ago. In 2022, the agency concluded that the safety of CBD as a novel food could not be established because available research contained too many uncertainties. Scientists highlighted potential concerns involving the liver, gastrointestinal system, endocrine function, nervous system, psychological effects and reproductive health. Much of the human evidence came from pharmaceutical studies involving considerably higher therapeutic CBD doses, while animal research often used materials that were not directly comparable with commercial food supplements.
EFSA revisited the evidence in a major update adopted in December 2025 and published in February 2026. Although the new scientific literature did not eliminate many of the earlier uncertainties, the agency determined that sufficient toxicological information was available to establish a provisional safe level for certain highly purified CBD supplements. The resulting 2-milligram figure applies only where CBD purity is at least 98 percent, the manufacturing process raises no additional safety concerns, genotoxicity has been ruled out and the formulation does not expose consumers to problematic small particles or nanoparticles. This framework provided the basis for EFSA to resume making product-specific decisions on individual CBD novel food applications.
Liver Effects Played a Major Role in Setting the Safety Limit
The scientific assessment of the synthetic product relied heavily on toxicological studies submitted by the applicant, including a 90-day oral toxicity study in rats. Researchers identified the liver as a key target organ, with female animals appearing more sensitive than males. EFSA used increased liver weight relative to body weight as an important endpoint when establishing the level from which the human safety limit would be calculated.
The agency identified a benchmark dose lower confidence limit of 10.5 milligrams of CBD per kilogram of body weight per day for the liver effect and then applied an uncertainty factor of 400. Such a large margin reflects the remaining gaps in the CBD evidence base and the need to account for differences between experimental animals and humans as well as variation within the human population. The calculation produced a safe level of approximately 0.026 milligrams per kilogram per day, which EFSA rounded to 2 milligrams per day for an adult. The agency also found no genotoxicity concern for the specific ingredient and concluded that consumption at the proposed level was not nutritionally disadvantageous.
Medication Interactions Remain a Significant Unresolved Concern
EFSA’s refusal to extend its safety conclusion to consumers taking medications is especially important because CBD is known to affect enzymes involved in processing numerous pharmaceutical drugs. Cannabidiol can influence cytochrome P450 enzymes and other metabolic pathways, potentially altering how quickly certain medicines are broken down by the body. Depending on the drug involved, that interaction could potentially increase or decrease circulating medication levels.
The issue illustrates why CBD’s regulatory treatment as a food ingredient differs from simply determining whether the cannabinoid is intoxicating. CBD generally does not produce the characteristic high associated with THC, but that does not mean it is pharmacologically inactive. Cannabidiol is the active ingredient in the prescription medicine Epidyolex, which is authorized in Europe for certain severe seizure disorders at pharmaceutical doses. Food regulators must therefore consider whether repeated exposure through supplements could produce biological effects or interact with medicines even at doses far below those used therapeutically.
A Positive EFSA Opinion Is Not Yet an EU Market Approval
The distinction between EFSA’s role and the European Commission’s authority is essential. EFSA performs the scientific risk assessment, determining whether the evidence supports the safety of a proposed novel food under specified conditions. The Commission then considers that opinion as part of the formal authorization process. A CBD product cannot legally enter the EU novel food market simply because EFSA has issued a positive assessment.
Under the European novel food system, the Commission generally prepares a draft implementing act after a favorable scientific opinion and submits it to the Standing Committee on Plants, Animals, Food and Feed, which represents EU member states. If the measure receives the required support and is formally adopted, the Commission updates the Union list of authorized novel foods. The authorization can establish specifications, maximum intake levels, labeling requirements, target-population restrictions and potentially post-market monitoring conditions. Only after that process is completed can the novel food be legally marketed under the authorization.
Proprietary Research Could Give the Applicant a Temporary Advantage
The synthetic CBD application also contains an important commercial element. EFSA stated that it could not have reached its positive conclusion without certain proprietary information supplied by the applicant. Those materials included manufacturing information, stability testing and key toxicological studies. Chanelle McCoy CBD requested data protection for portions of the dossier under EU novel food rules.
European law allows qualifying proprietary scientific evidence supporting a novel food authorization to receive protection for five years. If the Commission grants that protection, other companies generally cannot rely on the protected information to market the same novel food during the protection period without permission from the original applicant. Competitors can still pursue their own authorizations using independent evidence. For an industry that has spent years waiting for a workable CBD pathway, however, being among the first companies to complete the scientific assessment could carry considerable commercial value.
The Decision Does Not Automatically Clear Plant-Derived CBD
The positive synthetic CBD opinion should not be interpreted as a universal approval of cannabis-derived cannabidiol. EFSA evaluates novel food applications individually, including the exact manufacturing process, chemical composition, purity, contaminants, particle characteristics and toxicology associated with each ingredient. A synthetic molecule can be highly standardized, making it easier to characterize impurities and demonstrate consistency between production batches.
Plant-derived CBD products can be more complex. Hemp extracts may contain additional cannabinoids, terpenes, plant compounds and processing residues that require separate evaluation. In 2026, EFSA continued issuing opinions on several cannabis-derived novel food applications, including CBD isolates and broader hemp extracts, with some products failing to establish safety under their proposed conditions. One plant-derived CBD isolate proposed at 21 milligrams per day, for example, did not receive a positive safety conclusion because uncertainties remained regarding the formulation, small particles and whether the toxicological testing adequately represented the product intended for market.
The 2-Milligram Limit Could Reshape Europe’s CBD Market
For manufacturers, the positive scientific opinion offers both an opportunity and a challenge. The opportunity is clear: Europe may finally have a viable regulatory pathway for legally authorized CBD food supplements. The challenge is that the 2-milligram daily intake established by EFSA is dramatically below many existing commercial CBD serving sizes. Products historically marketed with 10, 20, 25 or more milligrams per serving could not simply use this decision as justification for their current formulations.
The low limit could encourage companies to reformulate products, develop micro-dose supplements or generate additional toxicological evidence capable of supporting higher intake levels in future applications. It may also divide the market between highly standardized CBD ingredients able to satisfy strict novel food specifications and less-characterized extracts that face greater regulatory difficulty. Manufacturers investing in pharmaceutical-style quality control, batch consistency, impurity testing and long-term toxicology may ultimately gain an advantage as European regulators move away from the largely unregulated CBD market that developed during the cannabinoid’s early commercial boom.
The UK Is Following a Separate but Related CBD Path
The European Union is not the only European market moving toward formal CBD food authorizations. Following Brexit, the United Kingdom operates its own novel food system. British regulators have already completed positive safety assessments for several high-purity CBD applications and in 2026 moved toward recommendations for the country’s first CBD novel food authorizations.
The British approach has not been identical to EFSA’s. The UK Food Standards Agency previously established a provisional acceptable daily intake of 10 milligrams of CBD for healthy adults, substantially higher than EFSA’s current 2-milligram provisional level. The differing numbers illustrate how regulators evaluating much of the same cannabinoid can reach different risk-management positions based on the evidence, uncertainty factors and regulatory frameworks they use. The divergence could eventually create separate EU and UK CBD markets with different serving sizes and labeling requirements.
A Potential Turning Point for CBD Regulation in Europe
CBD’s European regulatory journey has been defined by years of uncertainty. Products became widely available before regulators had completed the scientific work needed to determine how cannabidiol should fit into food law. The EU’s novel food framework subsequently created a formal pre-market authorization requirement, but EFSA’s unresolved safety concerns effectively stalled much of the industry while companies attempted to provide the required toxicological evidence.
The positive synthetic CBD assessment shows that the regulatory barrier is no longer impossible to clear. EFSA has now demonstrated that a carefully characterized cannabidiol ingredient can receive a favorable scientific opinion when the manufacturing process is controlled, purity is high, toxicology is adequate and the proposed dose remains within the agency’s conservative safety limit. The Commission must still decide whether to authorize the product, and the outcome will not legalize every CBD supplement already sold across Europe. Even so, the decision could mark the beginning of a new phase in which CBD moves from a regulatory gray area toward a tightly controlled category of officially authorized food supplements. If the Commission follows EFSA’s recommendation and adds the synthetic cannabidiol to the Union list, Europe will have taken one of its most important steps yet toward establishing a permanent legal market for CBD foods.
